SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (18858)2/17/1999 6:48:00 PM
From: Mkilloran  Read Replies (1) | Respond to of 23519
 
Dais...and with Muse sales in the UK,etc recovering to pre-Viagra sales numbers we can expect higher sales reporting in the 1st qtr 1999 from Astra.

Astra was not detailing to the PCP's until this qtr. And with the combined EU sales force of Astra and Zeneca being introduced to MUSE next week all we need is more countries to launch MUSE.

Everything should be inplace soon for a very nice 2nd qtr 1999.



To: DaiS who wrote (18858)2/17/1999 6:56:00 PM
From: betty moyers  Respond to of 23519
 
Dais, Thanks I will study and ponder your excellent finding of Astra results and search the web site for more. Back later. regards.



To: DaiS who wrote (18858)2/17/1999 7:05:00 PM
From: Mkilloran  Respond to of 23519
 
Dais...if you project out the population of EU and the sales results of Muse with the expected launch of all of the EU countries in the 1st and 2nd qtr 1999.

We can expect to see Astra/Zeneca EU sales in the 3rd qtr between $20-22 million US.

This could be higher based on the success of Astra/Zeneca marketing to the PCP's in Europe.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News